Compare NTGR & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTGR | ZURA |
|---|---|---|
| Founded | 1996 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 606.4M | 595.9M |
| IPO Year | 2000 | N/A |
| Metric | NTGR | ZURA |
|---|---|---|
| Price | $21.55 | $5.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $39.00 | $11.78 |
| AVG Volume (30 Days) | 347.5K | ★ 482.0K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.64 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.75 | $0.99 |
| 52 Week High | $36.86 | $7.25 |
| Indicator | NTGR | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 42.39 |
| Support Level | $21.30 | $5.62 |
| Resistance Level | $21.88 | $6.99 |
| Average True Range (ATR) | 0.71 | 0.50 |
| MACD | 0.16 | -0.12 |
| Stochastic Oscillator | 66.26 | 5.19 |
Netgear Inc provider of networking technologies for businesses, homes, and service providers. It delivers a wide range of intelligent solutions designed to unleash the full potential of connectivity. The group has two segments: Enterprise and Consumer which offers reliable, easy-to-use, high-performance networking solutions, including switches, routers, access points, software, and AV over IP technologies, tailored to meet the diverse needs of organizations of all sizes. The Home Networking and Mobile offers connectivity, powerful performance, and enhanced security features right out of the box, designed to help keep families safe online, and Others. It conduct business across three geographic territories: Americas; Europe, Middle East and Africa; and Asia Pacific.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.